HELIX BIOPHARMA CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.195 CAD | +2.63% |
|
+11.43% | -7.14% |
| Apr. 08 | Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding | CI |
| Mar. 28 | Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 57.51M |
|---|---|---|---|---|---|
| Net income 2022 | -6M -8.21M | Net income 2023 | -6M -8.21M | EV / Sales 2022 | - |
| Net cash position 2022 | 784K 1.07M | Net cash position 2023 | 808K 1.11M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 84.24% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.63% | ||
| 1 week | +11.43% | ||
| Current month | +8.33% | ||
| 1 month | -7.14% | ||
| 3 months | -9.30% | ||
| 6 months | -2.50% | ||
| Current year | -7.14% |
1 week
0.18
0.20
1 month
0.160.20
Current year
0.160.25
1 year
0.150.26
3 years
0.150.97
5 years
0.152.01
10 years
0.152.35
| Managers | Title | Age | Since |
|---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
| Director of Finance/CFO | 59 | Feb. 13 | |
| Chief Tech/Sci/R&D Officer | - | 22-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 22-04-17 | |
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Malgorzata Laube
BRD | Director/Board Member | - | 22-12-07 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 0.195 | +2.63% | 2,000 |
| 24-04-23 | 0.19 | 0.00% | 20,272 |
| 24-04-22 | 0.19 | +8.57% | 2,000 |
| 24-04-17 | 0.175 | -12.50% | 5,056 |
Delayed Quote Toronto S.E., April 24, 2024 at 09:30 am EDT
More quotes
Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).
Calendar
2024-06-10
- Q3 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -7.14% | 32.61M | |
| +4.09% | 43.84B | |
| +47.81% | 41.25B | |
| +9.45% | 41.68B | |
| -10.92% | 27.04B | |
| +9.32% | 25.53B | |
| -24.87% | 18.18B | |
| +29.70% | 12.29B | |
| +1.28% | 12.29B | |
| +7.78% | 11.15B |
- Stock Market
- Equities
- HBP Stock
